Search Results - "Boussios, Stergios"

Refine Results
  1. 1

    Frontiers of Ovarian Carcinosarcoma by Ismail, Ayden, Choi, Sunyoung, Boussios, Stergios

    Published in Current treatment options in oncology (01-12-2023)
    “…Opinion statement Ovarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts…”
    Get full text
    Journal Article
  2. 2

    Aberrations of DNA Repair Pathways in Prostate Cancer-The State of the Art by Boussios, Stergios, Sheriff, Matin

    “…Prostate cancer (PC) is the second most commonly diagnosed cancer in males worldwide and the fifth most common cause of cancer-related death in men [...]…”
    Get full text
    Journal Article
  3. 3

    BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations by Shah, Sidrah, Rachmat, Rachelle, Enyioma, Synthia, Ghose, Aruni, Revythis, Antonios, Boussios, Stergios

    “…Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is implicated in cancer and DNA damage response (DDR) pathways are in…”
    Get full text
    Journal Article
  4. 4

    Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic by Ghose, Aruni, Moschetta, Michele, Pappas-Gogos, George, Sheriff, Matin, Boussios, Stergios

    “…Prostate cancer (PC) is the second most common cancer in men worldwide. Due to the large-scale sequencing efforts, there is currently a better understanding of…”
    Get full text
    Journal Article
  5. 5

    Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors by Aliyuda, Fine, Moschetta, Michele, Ghose, Aruni, Sofia Rallis, Kathrine, Sheriff, Matin, Sanchez, Elisabet, Rassy, Elie, Boussios, Stergios

    Published in Current cancer drug targets (01-01-2023)
    “…Ovarian cancer has become the largest cause of gynaecological cancer-related mortality. It is typically diagnosed at a late stage and has no effective…”
    Get more information
    Journal Article
  6. 6

    Frontiers of Molecular Biology of Cancer by Boussios, Stergios, Sanchez, Elisabet, Sheriff, Matin

    “…Cancer is rooted in genetic background, with the expression of oncogenesis playing a pivotal role in the early stages of tumor formation [...]…”
    Get full text
    Journal Article
  7. 7

    HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK by Choi, Sunyoung, Ismail, Ayden, Pappas-Gogos, George, Boussios, Stergios

    Published in Pathogens (Basel) (01-02-2023)
    “…Cervical cancer is the fourth most common malignancy in females worldwide, and a leading cause of death in the United Kingdom (UK). The human papillomavirus…”
    Get full text
    Journal Article
  8. 8

    Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer by Saxby, Helen, Boussios, Stergios, Mikropoulos, Christos

    “…Stereotactic ablative body radiotherapy (SABR) is currently used as a salvage intervention for men with oligometastatic prostate cancer (PC), and increasingly…”
    Get full text
    Journal Article
  9. 9

    State-of-the-Art Molecular Oncology in UK by Sandoughdaran, Saleh, Mikropoulos, Christos, Boussios, Stergios

    “…Molecular oncology is a rapidly evolving field that focuses on the genetic and molecular basis of cancer [...]…”
    Get full text
    Journal Article
  10. 10

    Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach by Boussios, Stergios, Karihtala, Peeter, Moschetta, Michele, Abson, Charlotte, Karathanasi, Afroditi, Zakynthinakis-Kyriakou, Nikolaos, Ryan, Jake Edward, Sheriff, Matin, Rassy, Elie, Pavlidis, Nicholas

    Published in Investigational new drugs (01-02-2020)
    “…Summary Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery…”
    Get full text
    Journal Article
  11. 11

    Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond by Boussios, Stergios, Abson, Charlotte, Moschetta, Michele, Rassy, Elie, Karathanasi, Afroditi, Bhat, Tahir, Ghumman, Faisal, Sheriff, Matin, Pavlidis, Nicholas

    Published in Drugs in R&D (01-06-2020)
    “…Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose)…”
    Get full text
    Journal Article
  12. 12

    Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets by Ioannidou, Evangelia, Moschetta, Michele, Shah, Sidrah, Parker, Jack Steven, Ozturk, Mehmet Akif, Pappas-Gogos, George, Sheriff, Matin, Rassy, Elie, Boussios, Stergios

    “…Prostate cancer (PC) is the most common cancer in men and the second leading cause of cancer-related death worldwide. Many therapeutic advances over the last…”
    Get full text
    Journal Article
  13. 13

    Applications of Proteomics in Ovarian Cancer: Dawn of a New Era by Ghose, Aruni, Gullapalli, Sri Vidya Niharika, Chohan, Naila, Bolina, Anita, Moschetta, Michele, Rassy, Elie, Boussios, Stergios

    Published in Proteomes (09-05-2022)
    “…The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous…”
    Get full text
    Journal Article
  14. 14

    Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review by Boussios, Stergios, Karihtala, Peeter, Moschetta, Michele, Karathanasi, Afroditi, Sadauskaite, Agne, Rassy, Elie, Pavlidis, Nicholas

    Published in Diagnostics (Basel) (01-08-2019)
    “…Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a…”
    Get full text
    Journal Article
  15. 15

    An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer by Saxby, Helen, Mikropoulos, Christos, Boussios, Stergios

    Published in Diagnostics (Basel) (31-07-2020)
    “…Serum biomarkers are molecules produced by normal and abnormal cells. Prostate specific antigen (PSA) is an example of a serum biomarker used widely in the…”
    Get full text
    Journal Article
  16. 16

    Exosomes in the Diagnosis and Treatment of Renal Cell Cancer by Boussios, Stergios, Devo, Perry, Goodall, Iain C. A, Sirlantzis, Konstantinos, Ghose, Aruni, Shinde, Sayali D, Papadopoulos, Vasileios, Sanchez, Elisabet, Rassy, Elie, Ovsepian, Saak V

    “…Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from renal tubular epithelial cells, with clear cell RCC comprising…”
    Get full text
    Journal Article
  17. 17

    Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer by Parent, Pauline, Marcq, Gautier, Adeleke, Sola, Turpin, Anthony, Boussios, Stergios, Rassy, Elie, Penel, Nicolas

    Published in Therapeutic Advances in Medical Oncology (01-01-2023)
    “…Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not…”
    Get full text
    Book Review Journal Article
  18. 18

    Exosomes in Renal Cell Cancer: Diagnostic and Therapeutic Nanovehicles by Boussios, Stergios, Ovsepian, Saak V

    Published in Technology in cancer research & treatment (01-01-2024)
    “…Early diagnosis is crucial for enhancing the survival rate of renal cell cancer patients, and exosomes present potential advantages in this area. Their small…”
    Get full text
    Journal Article
  19. 19

    The Developing Story of Predictive Biomarkers in Colorectal Cancer by Boussios, Stergios, Ozturk, Mehmet Akif, Moschetta, Michele, Karathanasi, Afroditi, Zakynthinakis-Kyriakou, Nikolaos, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Pavlidis, Nicholas

    Published in Journal of personalized medicine (07-02-2019)
    “…Colorectal cancer (CRC) is the third most common malignancy worldwide. Surgery remains the most important treatment for non-metastatic CRC, and the…”
    Get full text
    Journal Article
  20. 20

    Large Language Models in Oncology: Revolution or Cause for Concern? by Caglayan, Aydin, Slusarczyk, Wojciech, Rabbani, Rukhshana Dina, Ghose, Aruni, Papadopoulos, Vasileios, Boussios, Stergios

    Published in Current oncology (Toronto) (01-04-2024)
    “…The technological capability of artificial intelligence (AI) continues to advance with great strength. Recently, the release of large language models has taken…”
    Get full text
    Journal Article